Edwards Lifesciences Corp. Receives Hold Rating from RBC Capital (EW)
Edwards Lifesciences Corp. (NYSE:EW)‘s stock had its “hold” rating reiterated by analysts at RBC Capital in a research report issued to clients and investors on Thursday, AnalystRatingsNetwork.com reports. They currently have a $75.00 target price on the stock. RBC Capital’s target price would indicate a potential upside of 4.41% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp. (NYSE:EW) from $81.00 to $82.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences Corp. (NYSE:EW) in a research note to investors on Tuesday, September 10th. They now have a $90.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Edwards Lifesciences Corp. (NYSE:EW) from an “underperform” rating to a “neutral” rating in a research note to investors on Thursday, August 29th. They now have a $74.00 price target on the stock. One analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $80.75.
Edwards Lifesciences Corp. (NYSE:EW) traded down 0.61% on Thursday, hitting $71.395. 277,390 shares of the company’s stock traded hands. Edwards Lifesciences Corp. has a 1-year low of $62.34 and a 1-year high of $110.79. The stock’s 50-day moving average is $70.96 and its 200-day moving average is $71.31. The company has a market cap of $8.016 billion and a P/E ratio of 21.00.
Edwards Lifesciences Corp. (NYSE:EW) last released its earnings data on Thursday, July 25th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.06. The company had revenue of $517.20 million for the quarter, compared to the consensus estimate of $514.59 million. During the same quarter in the previous year, the company posted $0.57 earnings per share. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp. will post $3.07 EPS for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.